

mTOR Signaling Plays a Critical Role in the Defects Observed in Muscle-Derived Stem/Progenitor Cells Isolated From a Murine Model of Accelerated Aging

Koji Takayama,^{1,2,3} Yohei Kawakami,^{1,2,3} Mitra Lavasani,^{1,2} Xiaodong Mu,^{1,2,4,5} James H. Cummins,^{1,2,4} Takashi Yurube,¹ Ryoosuke Kuroda,³ Masahiro Kurosaka,³ Freddie H. Fu,¹ Paul D. Robbins,⁶ Laura J. Niedernhofer,⁶ Johnny Huard^{1,2,4,5}

¹Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh 15213, Pennsylvania, ²Stem Cell Research Center, University of Pittsburgh, Pittsburgh 15219, Pennsylvania, ³Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan, ⁴Department of Orthopaedic Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, South Campus Research Building #3, 1881 East Rd (3SCR) 6th Floor; Room 3708, Houston 77054, Texas, ⁵Center for Regenerative Sports Medicine, Steadman Philippon Research Institute, Vail 81657, Colorado, ⁶Department of Metabolism and Aging, The Scripps Research Institute Florida, Jupiter 33458, Florida

Received 4 December 2015; accepted 26 August 2016

Published online 22 September 2016 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jor.23409

ABSTRACT: Mice expressing reduced levels of ERCC1-XPF (*Ercc1*^{-Δ} mice) demonstrate premature onset of age-related changes due to decreased repair of DNA damage. Muscle-derived stem/progenitor cells (MDSPCs) isolated from *Ercc1*^{-Δ} mice have an impaired capacity for cell differentiation. The mammalian target of rapamycin (mTOR) is a critical regulator of cell growth in response to nutrient, hormone, and oxygen levels. Inhibition of the mTOR pathway extends the lifespan of several species. Here, we examined the role of mTOR in regulating the MDSPC dysfunction that occurs with accelerated aging. We show that mTOR signaling pathways are activated in *Ercc1*^{-Δ} MDSPCs compared with wild-type (WT) MDSPCs. Additionally, inhibiting mTOR with rapamycin promoted autophagy and improved the myogenic differentiation capacity of the *Ercc1*^{-Δ} MDSPCs. The percent of apoptotic and senescent cells in *Ercc1*^{-Δ} MDSPC cultures was decreased upon mTOR inhibition. These results establish that mTOR signaling contributes to stem cell dysfunction and cell fate decisions in response to endogenous DNA damage. Therefore, mTOR represents a potential therapeutic target for improving defective, aged stem cells. © 2016 The Authors. *Journal of Orthopaedic Research* Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. *J Orthop Res* 35:1375–1382, 2017.

Keywords: biology; muscle; ERCC1-XPF; mTOR; stem cells; aging; progeria; senescence

Aging can be viewed as a progressive decline in the function of cells, tissues, and organs. The molecular basis underlying aging and age-related degenerative changes remains unclear¹; however, it is believed that these changes are driven by time-dependent accumulation of stochastic molecular and cellular damage.^{1,2} Consistent with this theory, the majority of human progeroid syndromes, or diseases of accelerated aging, are caused by defects in mechanisms required for genome maintenance.³ This suggests that DNA damage is one type of stochastic molecular instability that promotes age-related degenerative changes.

Murine models of progeroid syndromes have been studied extensively, with the aim of elucidating the

relationship between DNA damage and age-related functional decline. Excision repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum complementation group F (XPF) form a heterodimeric endonuclease that is required for numerous DNA repair mechanisms.^{4,5} XPF encodes the catalytic subunit of the endonuclease, while ERCC1 serves as an essential binding partner that enables the repair of damaged DNA.⁶ Reduced expression of XPF due to a mutation in the *XPF* gene causes XFE progeroid syndrome.⁷ This was recapitulated in the mouse by a mutation of the *mErcc1* locus to titrate the expression of ERCC1-XPF.⁸ *Ercc1*^{-Δ} mice, harboring one knock-out and one hypomorphic allele of *Ercc1*, express 5–10% of the normal level of the nuclease and have a maximum lifespan of 28 weeks.⁹ These mice demonstrate spontaneous and premature onset of age-related changes in the epidermal, hematopoietic, endocrine, hepatobiliary, renal, nervous, and musculoskeletal systems, identical to XFE progeroid syndrome.^{9–13} In addition, the alterations in histopathology, pathophysiology, and genome-wide transcriptional reprogramming observed in this animal model correlate with those observed in naturally aged mice.¹⁴

Muscle-derived stem/progenitor cells (MDSPCs) are multipotent cells isolated from postnatal skeletal muscle through an established preplate technique.^{15–17} They exhibit many important stem cell characteristics including long-term proliferation, resistance to oxidative and inflammatory stresses, multi-lineage differentiation, and self-renewal capacities. MDSPCs can improve the regeneration of bone, and skeletal and

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

[Correction added on 29 September 2016, after first online publication: Correct version of the manuscript presented here.]

Koji Takayama and Yohei Kawakami contributed equally to this work.

Conflicts of interest: Johnny Huard wishes to disclose that he has received remuneration as a consultant and royalties from Cook Myosite, Inc. PR and LN receive research support from Aldabra Biosciences, of which they are cofounders.

Grant sponsor: NIH; Grant numbers: R21 AG033907, PO1 AG043376; Grant sponsor: University of Pittsburgh.

Correspondence to: Johnny Huard (T: +713-486-5427; F: +713-796-9697; E-mail: johnny.huard@uth.tmc.edu; jhuard@sprivail.org)

© 2016 The Authors. *Journal of Orthopaedic Research* Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society

cardiac muscle, mainly through the induction of neovascularization.^{15,18–20} A recent study demonstrated that cell proliferation and multi-lineage differentiation of MDSPCs isolated from progeroid *Ercc1*^{-Δ} mice were comparable to those of MDSPCs isolated from old WT mice, but considerably impaired relative to those of MDSPCs isolated from young-WT mice.²¹ Furthermore, fewer cells expressing stem/progenitor cell markers were found in the skeletal muscle of these progeroid mice compared to young-WT mice.²¹ The reduction in number and increased dysfunction of MDSPCs contributes to age-related loss of tissue function since the transplantation of functional young-WT MDSPCs into progeroid mice extends their lifespan and healthspan.²¹ This is also the case with naturally aged normal rodents; transplantation of mesenchymal stem cells extends the health and lifespan of old rats.²²

It has been proposed that the mammalian target of rapamycin (mTOR) signaling pathways play a role in the progression of aging,²³ and it has been shown that inhibiting mTOR in yeast, worms, and flies extends their life-spans.^{24,25} Notably, rapamycin, an inhibitor of mTOR, administered at a late stage in the life of genetically heterogeneous mice, significantly extends their lifespan.²⁶ Downstream factors in the mTOR pathway including the 70-kDa ribosomal protein S6 kinase (*p70S6K*) and eIF4-Ebinding protein 1 (4E-BP1) bind to mRNA and regulate translation, thereby controlling the rate of protein synthesis and consequently cell growth.²⁷ Increased lifespan could also be explained by increased autophagy in response to mTOR inhibition. Autophagy is the controlled self-degradation of damaged, redundant, or hazardous cellular components, ranging from individual proteins (microautophagy) to entire organelles (macroautophagy). Both protein synthesis and autophagy are considered to be critical in the regulation of lifespan by mTOR.²⁸

The purpose of this study was to determine if mTOR signaling also plays a role in stem cell dysfunction as it relates to aging. We hypothesized that inhibiting mTOR would rescue the defect, at least in part, in *Ercc1*^{-Δ} MDSPCs, and could represent a target to delay aging. Our study not only demonstrates a correlation between MDSPC dysfunction and mTOR activity, but also shows that exposing progeroid MDSPCs to rapamycin promoted myogenic differentiation, while attenuating apoptosis and cellular senescence.

MATERIALS AND METHODS

Isolation of MDSPCs

All animal experiments were performed with the approval of the University of Pittsburgh's Institutional Animal Care and Use Committee. MDSPCs were isolated via a modified preplate technique, as previously described,^{15,16,21} from adult WT (19-week-old) and progeroid *Ercc1*^{-Δ} (19-week-old) mice (*n* = 4 per strain), which were bred at the University of Pittsburgh's Division of Laboratory Animal Research. MDSPCs were cultured in proliferation medium (PM), which contains Dulbecco's modified Eagle's medium (DMEM), 10% fetal bovine serum (FBS), 10% horse serum, 1% penicillin/

streptomycin (all from Invitrogen, Waltham, MA), and 0.5% chick embryo extract (Accurate Chemical and Scientific Corporation, Westbury, NY). The isolated MDSPCs were plated on collagen type I-coated 25 cm² flasks at a density of 3 × 10⁵ cells per well in PM. At 70% confluence, the cells were dissociated with trypsin/EDTA, replated at a cell density of 1.0–2.5 × 10³ cells/cm², and cultured for 3–4 weeks before performing the cell treatments described below.

Rapamycin Treatment

Rapamycin was obtained from LC Laboratories (Woburn, MA), dissolved in dimethyl sulphoxide (DMSO) at 50 mg/ml, and stored at -20°C. MDSPCs from *Ercc1*^{-Δ} and WT mice were treated with 10 nM rapamycin in order to inhibit mTOR. As a control, the same amount of DMSO was used to treat MDSPCs from these two populations.

Proliferation Assay

MDSPCs were plated on collagen type I-coated 25 cm² flasks at a density of 2,000 cells per well. Live-cell imaging was performed using an imaging system equipped with a 20× objective lens (Automated Cell Technologies, Pittsburgh, PA). Images were obtained at 10 min intervals over a period of 72 h, and 10 of these images were randomly selected for analysis at four separate time points during the experiment (0, 24, 48, and 72 h).

Apoptosis Assay

Apoptotic cell death was evaluated in cultured cells using the In situ Cell Death Detection kit containing fluorescein (Roche Applied Science, Penzberg, Germany) for TUNEL detection according to the manufacturer's protocol. To visualize the nuclei, the cultures were incubated with 4',6-diamidino-2-phenylindole (DAPI) for 10 min. The presence of fluorescein as a cell death marker was visualized using a Leica DMIRB microscope. The number of cells that were TUNEL-positive was calculated and averaged across 15 fields each from three replicate plates for each of four independent experiments. The percentage of apoptotic cells was calculated as TUNEL-positive cells divided by the total number of cells, and then multiplied by 100.

Cellular Senescence Assay

Cellular senescence was evaluated in cultured cells using a Senescence β-Galactosidase Staining Kit (Cell Signaling Technology, Danvers, MA) to measure SA-β-gal activity, according to the manufacturer's protocol. Images were captured using a Leica DMIRB microscope. The number of cells that were SA-β-gal-positive was calculated and averaged across 15 fields each from three replicate plates for each of four independent experiments. The percentage of senescent cells was calculated as SA-β-gal-positive cells divided by the total number of cells and then multiplied by 100.

Myogenic Differentiation Assay

MDSPCs were plated in PM at a density of 1,000 cells/cm² and cultured for 3 days. The cells were then placed in DMEM supplemented with 2% FBS for an additional 4 days to induce myogenic differentiation, as described previously,²¹ with or without 10 nM rapamycin. On day 7, immunostaining was performed to detect fast myosin heavy chain (f-MyHC) expression, a marker of terminal myogenic differentiation. Cold methanol-fixed cultures were blocked with 5% goat serum and incubated with f-MyHC mouse monoclonal antibody (1:250; Sigma-Aldrich, St. Louis, MO), secondary biotinylated IgG (1:250; Vector Laboratories, Burlingame, CA) for 1 h, and

streptavidin-594 (1:500; Sigma–Aldrich) for 15 min to fluorescently label the myotubes. Nuclei were counter stained with DAPI (100 ng/ml; Sigma–Aldrich) for 10 min. The presence of fluorescein was visualized using a Leica DMIRB microscope equipped with a Retiga digital camera and evaluated using Northern Eclipse software (v. 6.0; Empix Imaging). Myogenic differentiation was calculated as the percentage of cells expressing f-MyHC. Data from three replicate plates from each of four independent experiments were analyzed. Total RNA was also extracted as described below for quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis. Expression of the myogenic genes *MyHC* and *Desmin* were also analyzed.

SDS-PAGE and Immunoblotting

Cells were lysed in Laemmli Sample Buffer (Bio-Rad Laboratories, Hercules, CA), boiled for 5 min, and centrifuged at 4,000 rpm for 5 min. The samples were loaded on a 4–12% SDS-polyacrylamide gel, transferred to an Immobilon polyvinylidene difluoride (PVDF) transfer membrane (Merck Millipore, Billerica, MA) and probed with primary antibodies followed by horseradish peroxidase (HRP)-conjugated secondary antibody. Proteins were visualized with ECL Plus reagent (GE Healthcare, Chicago, IL), and the chemical luminescent reaction visualized using a FOTO/Analyst Luminary/Fx CCD imaging system (Fotodyne, Inc., Hartland, WI). The following antibodies were used in this study: Rabbit anti-mTOR, rabbit anti-phospho-mTOR (*p*-mTOR), rabbit anti-phospho-4E-BP1 (*p*-4E-BP1) (Thr37/46), rabbit anti-phospho-p70-S6 (*p*-p70-S6) kinase (Thr389), rabbit anti-LC3, rabbit anti-poly (ADP-ribose) polymerase (PARP), rabbit anti-p16, rabbit anti-p21, rabbit anti-glyceraldehyde phosphate dehydrogenase (GAPDH), HRP-conjugated goat anti-rabbit IgG, and HRP-conjugated goat anti-mouse IgG (all antibodies were from Cell Signaling Technology). The intensities of the bands were quantified using image analysis software, ImageJ version (NIH Image). Values were normalized relative to GAPDH expressions.

RNA Isolation and Quantitative RT-PCR

Total RNA was extracted using the QIAshredder homogenizer and the RNeasy Mini kit (Qiagen; Venlo, Netherlands) according to the manufacturer's protocol. One microgram of total RNA was used for random hexamer-primed cDNA synthesis using a Super Script II pre-amplification system (Invitrogen). Quantitative RT-PCR reactions were performed in triplicate using iQ5 (Bio-Rad) and Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific, Waltham, MA) and 300 nM of each of the primers. The primers were designed based on the sequences in the GenBank database. The primer pairs used for this study are shown in Table 1. Electrophoretic separation on a 2.5% agarose gel was performed to ensure accurate outcomes of the reactions.

Statistical Analysis

The data were expressed as the mean \pm standard deviation (SD). For multiple comparisons, one-way ANOVA or the Kruskal–Wallis tests were applied. Pair-wise multiple comparisons were performed using the Tukey–Kramer or Scheffe's post hoc test. Data analyses were performed using PASW Statistics 21 (SPSS, Chicago, IL). Statistical significance was accepted at $p < 0.05$.

RESULTS

mTOR Signaling Is Elevated in MDSPCs Isolated From Progeroid *Ercc1*^{-Δ} Mice

To test the hypothesis that mTOR signaling contributes to the age-related dysfunction seen in MDSPCs isolated from progeroid *Ercc1*^{-Δ} mice, the phosphorylation of downstream signaling components of the mTOR pathway was examined by immunoblotting (Fig. 1A). The expression of *p*-mTOR, *p*-4E-BP1, and *p*-p70-S6 kinase in *Ercc1*^{-Δ} MDSPCs was increased compared with WT MDSPCs (*p*-mTOR: $p < 0.001$, *p*-4E-BP1: $p < 0.001$, *p*-p70-S6: $p < 0.001$). Rapamycin treatment significantly decreased the expression of *p*-mTOR and *p*-p70-S6 kinase in *Ercc1*^{-Δ} MDSPCs (*p*-mTOR: $p < 0.001$, *p*-p70-S6: $p < 0.001$). However, *p*-4E-BP1 was not significantly reduced upon rapamycin treatment ($p = 0.506$) (Fig. 1B). Of note, rapamycin had no significant effect on the baseline activity of mTOR in WT MDSPCs.

Rapamycin Increases Autophagy in MDSPCs Isolated From Progeroid *Ercc1*^{-Δ} Mice

Recent studies have provided evidence that a decline in autophagy, which is regulated by mTOR, contributes to aging.^{29,30} We next measured LC3 expression, which correlates with autophagic activity.³¹ Immunoblotting analysis revealed that the amount of LC3-II was significantly lower in *Ercc1*^{-Δ} MDSPCs compared to WT MDSPCs ($p < 0.001$) (Fig. 1C and D). Treatment with rapamycin significantly increased the amount of LC3-II in the *Ercc1*^{-Δ} MDSPC population ($p < 0.001$) (Fig. 1D).

Rapamycin Increases the Proliferation Capacity of MDSPCs From Progeroid Mice

Proliferation of MDSPCs, measured by live cell imaging, was significantly lower in isolates from *Ercc1*^{-Δ} mice, compared to MDSPCs from WT mice, at both 48 and 72 h ($p < 0.001$). Treatment of the cells with rapamycin had no effect on the proliferation capacity of MDSPCs of either genotype (Fig. 1E).

Table 1. Primer Sequences and Product Size for Real-Time PCR

Gene		5' DNA Sequence 3'	Amplicon Length (bp)
<i>MyHC</i>	Forward	5'-CCAGGCTGCGGAGGCAATCA-3'	115
	Reverse	5'-GGCCAGCTGCTCTTTTCAGGTTCG-3'	
<i>Desmin</i>	Forward	5'-TTCCCTCGAGCAGGCTTCGG-3'	147
	Reverse	5'-GCCATAGGATGGCGCTCGGG-3'	
<i>GAPDH</i>	Forward	5'-CCGTCGTGGATCTGACGTG-3'	146
	Reverse	5'-GTTGCTGTTGAAGTCGAGG-3'	




Figure 1. Measuring mTOR activity and autophagy in MDSPCs isolated from progeroid *Ercc1*^{-/-} mice. (A) Shown is a representative image of immunoblotting to measure mTOR, p-mTOR, p-4E-BP1, and p-p70 S6 expression in MDSPCs isolated from *Ercc1*^{-/-} and WT mice cultured with and without rapamycin. (B) Quantification of p-mTOR, p-4E-BP1, and p-p70 S6 expression relative to GAPDH. Error bars indicate the standard deviation. Statistical significance was determined using one-way ANOVA or the Kruskal–Wallis test with Tukey–Kramer or Scheffe’s post hoc test ($n = 4$). ### $p < 0.001$ versus WT-DMSO, *** $p < 0.001$ versus *ERCC1*^{-/-}-DMSO. (C) Representative image of immunoblotting to measure autophagy markers LC3 I and II expression in MDSPCs isolated from *Ercc1*^{-/-} and WT mice cultured with and without rapamycin. (D) Quantification of LC3II expression relative to GAPDH expression. Error bars indicate the standard deviation. Statistical significance was determined using the Kruskal–Wallis test with Scheffe’s post hoc test ($n = 4$). ### $p < 0.001$ versus WT-DMSO, *** $p < 0.001$ versus *Ercc1*^{-/-}-DMSO. (E) Proliferation of MDSPCs measured using live-cell imaging. Error bars indicate the standard deviation. Statistical significance was determined using one-way ANOVA with Tukey–Kramer post hoc test ($n = 4$). ### $p < 0.001$ versus WT-DMSO.

Rapamycin Decreases Apoptosis of MDSPCs From Progeroid Mice

Some adult stem cell populations are dramatically affected by stress, leading to increased apoptosis.³² We next determined the level of apoptosis in MDSPCs using the TUNEL assay. The percent of TUNEL-positive cells was significantly higher among *Ercc1*^{-/-} MDSPCs than among WT MDSPCs ($p < 0.001$) (Fig. 2A and B). Rapamycin treatment significantly ($p < 0.001$) reduced the percentage of TUNEL-positive cells among *Ercc1*^{-/-} MDSPCs (Fig. 2B). Furthermore, an increase in the expression of cleaved PARP (apoptosis marker) was detected in MDSPCs from progeroid *Ercc1*^{-/-} mice relative to WT MDSPCs, and rapamycin treatment of the cells attenuated the expression of this apoptotic marker (Fig. 2C).

Rapamycin Decreases Premature Senescence of MDSPCs From Progeroid Mice

Cellular senescence is characterized by cell cycle arrest, which leads to an irreversible loss of the self-renewal and differentiation capacities of stem cells.³³ To determine the extent of senescence in MDSPCs isolated from *Ercc1*^{-/-} mice, senescence-associated beta-galactosidase (SA-β-gal) activity was measured. The percentage of SA-β-gal-positive cells was significantly higher in *Ercc1*^{-/-} MDSPCs than in WT MDSPCs ($p < 0.001$) (Fig. 3A). However, rapamycin treatment reduced the percentage of SA-β-gal-positive *Ercc1*^{-/-} MDSPCs ($p < 0.001$) (Fig. 3A). Moreover, increased expression of *p16* and *p21* were detected in the progeroid *Ercc1*^{-/-} MDSPCs compared to WT MDSPCs, and rapamycin treatment resulted in the




Figure 2. Measuring the effect of rapamycin on apoptosis in MDSPCs isolated from progeroid *Ercc1*^{-/-} mice. (A) Representative images of TUNEL assay. Live cells (DAPI: blue), apoptotic cells (yellow–green), and merged figures. Scale bar = 100 μm. (B) The percentage of TUNEL-positive cells was counted from images obtained from four independent MDSPC populations per genotype and treatment group. Error bars indicate the standard deviation. ### $p < 0.001$ versus WT-DMSO, *** $p < 0.001$ versus *ERCC1*^{-/-}-DMSO. Statistical significance was determined using the Kruskal–Wallis test with Scheffe’s post hoc test. (C) Immunoblotting to measure the expression of cleaved PARP, an apoptosis-related marker, in MDSPCs isolated from *Ercc1*^{-/-} and WT mice cultured with and without rapamycin.




Figure 3. Measuring the effect of rapamycin on senescence in MDSPCs isolated from progeroid *Ercc1*^{-/-} mice. (A) The histogram indicates the percent of SA β -gal-positive cells from four independent MDSPC populations from each genotype and treatment group. Error bars indicate the standard deviation. ###*p* < 0.001 versus WT-DMSO, ****p* < 0.001 versus *Ercc1*^{-/-}-DMSO. Statistical significance was determined using one-way ANOVA test with Scheffe's post hoc test. (B) Immunoblotting to measure the expression of senescence-related markers p16 and p21 in MDSPCs isolated from *Ercc1*^{-/-} and WT mice cultured with and without rapamycin.

lowered expression of these cell senescence markers in *Ercc1*^{-/-} MDSPCs (Fig. 3B).

Rapamycin Improves the Myogenic Differentiation Capacity of MDSPCs From Progeroid Mice

To determine whether the myogenic differentiation capacity of MDSPCs isolated from progeroid *Ercc1*^{-/-}

mice is affected by mTOR signaling, the cells were cultured to confluence and then switched to differentiation medium. In the presence or absence of rapamycin, WT MDSPCs fused to form multinucleated myotubes expressing f-MyHC, a marker of terminal myogenic differentiation (Fig. 4A and B). In contrast, cultures of MDSPCs isolated from the progeroid




Figure 4. Measuring the effect of rapamycin on the myogenic differentiation of MDSPCs isolated from progeroid *Ercc1*^{-/-} mice. (A) Images of in vitro myogenic differentiation. Cells were immunostained for the terminal differentiation marker, f-MyHC (red). Scale bar = 50 μ m. (B) Quantification of myogenic differentiation was calculated as the fraction of cells (DAPI, blue) expressing f-MyHC (red) from four independent MDSPC populations. Error bars indicate the standard deviation. Statistical significance was determined using one-way ANOVA test with Tukey-Kramer post hoc test. ###*p* < 0.001 versus WT-DMSO, ****p* < 0.001 versus *Ercc1*^{-/-}-DMSO. (C and D). Quantitative RT-PCR to measure the expression levels of the myogenic differentiation markers MyHC and desmin after myogenic differentiation of MDSPCs isolated from *Ercc1*^{-/-} and WT mice, cultured with and without rapamycin. Error bars indicate the standard deviation. Statistical significance was determined using one-way ANOVA test with Tukey-Kramer or Scheffe's post hoc test (*n* = 4). ###*p* < 0.001 versus WT-DMSO, ***p* < 0.01, ****p* < 0.001 versus *Ercc1*^{-/-}-DMSO.

Ercc1^{-Δ} mice had significantly fewer f-MyHC expressing cells, indicating an impairment in their differentiation capacity ($p < 0.001$) (Fig. 4B). Interestingly, rapamycin significantly improved the myogenic differentiation capacity of the *Ercc1*^{-Δ} MDSPCs ($p < 0.001$) (Fig. 4A and B). Impaired differentiation of *Ercc1*^{-Δ} MDSPCs was confirmed by measuring the expression of the myogenic differentiation markers myosin heavy chain (MyHC) and desmin. The expression levels of MyHC and desmin were significantly lower in MDSPCs isolated from the progeroid mice than in WT MDSPCs (MyHC: $p < 0.001$, desmin: $p < 0.001$). The expression levels of both proteins were increased upon rapamycin treatment (MyHC: $p < 0.001$, desmin: $p = 0.002$, respectively) (Fig. 4C and D).

DISCUSSION

In this study, we examined the role that mTOR plays in the myogenic differentiation, apoptosis, and senescence of MDSPCs isolated from a murine model of a human progeroid syndrome. Previous studies established that the cell proliferation and myogenic differentiation capacities of MDSPCs isolated from progeroid *Ercc1*^{-Δ} mice are similar to MDSPCs isolated from naturally aged mice and were significantly impaired relative to that of MDSPCs isolated from young-WT mice.²¹ Furthermore, fewer cells expressing stem/progenitor cell markers could be isolated from the skeletal muscle of these progeroid *Ercc1*^{-Δ} mice than from young-WT mice.²¹ Here, we demonstrate that MDSPCs isolated from this murine model of accelerated aging exhibit increased mTOR expression and a reduction in autophagy. Inhibiting mTOR in this adult stem cell population improved the myogenic capacity of the progeroid MDSPCs.

mTOR is a protein kinase that helps to integrate cellular activities in response to nutrients, stress, and extra-cellular signals, including hormones and locally produced growth factors.³⁴ The mTOR signaling pathways play multiple roles in adult animals that are involved in cell growth, aging, cancer, and metabolic disorders.³⁵ Hyperactivation of mTOR signaling has been reported in the cardiac and skeletal muscles of progeroid *Lmna*^{-/-} mice.³⁶ In accordance with these observations, hematopoietic stem cells (HSCs) from old mice have elevated mTOR activity, and increasing mTOR signaling in young mice induces premature aging.³⁷ Here, we show that mTOR activity is higher in MDSPCs isolated from progeroid mice than in WT MDSPCs (Fig. 1). These observations suggest that abnormally increased activation of the mTOR pathway could be involved in stem cell exhaustion/depletion, which has been linked with an accelerated aging phenotype.³⁸

mTOR regulates protein synthesis through the phosphorylation of 4E-BP1 and *p70-S6*.²⁷ Our results demonstrate that the phosphorylation of 4E-BP1 and *p70-S6* is increased in MDSPCs isolated from progeroid mice, and that the phosphorylation of *p70-S6* is

decreased following treatment with rapamycin. However, phosphorylation of the mTOR target 4E-BP1 does not change significantly following rapamycin treatment. Consistent with our findings, previous studies have reported that rapamycin has a greater effect on *p70-S6* kinase phosphorylation than on 4E-BP1 phosphorylation.³⁹ *p70-S6* is among the major downstream targets of the mTOR pathway; deletion of the *p70-S6* gene increases lifespan in mice⁴⁰ and retards the aging of bone, the immune system, and skeletal muscle.⁴¹

Another important function of the mTOR signaling pathway is the regulation of autophagy, a process in which the cell degrades damaged or excess cellular components, ranging from individual proteins and protein aggregates to whole organelles, through the lysosomal machinery of the cell. Recent studies have provided evidence that insufficient autophagy is implicated in normal aging.^{29,30,42,43} Stem cells lose their capacity to self-renew and differentiate when autophagy is disrupted; hence, the cells essentially lose their "stemness."⁴⁴ Interestingly, rapamycin treatment activates the clearance of progerin and consequently slows down the accelerated aging process.⁴⁵ In MDSPCs from progeroid *Ercc1*^{-Δ} mice, autophagy is significantly impaired relative to MDSPCs isolated from WT mice, but significantly increased in the presence of rapamycin. Therefore, it is possible that the loss of the differentiation potential of the MDSPCs is partially due to insufficient autophagy.

MDSPCs isolated from progeroid *Ercc1*^{-Δ} mice have significantly fewer f-MyHC expressing cells, consistent with their reduced myogenic differentiation capacity. However, inhibition of mTOR using rapamycin restores, at least in part, the myogenic differentiation capacity of MDSPCs. These results suggest that autophagy plays a crucial role in differentiation by regulating the efficient removal of sets of transcription factors, enzymes, adhesion molecules, or secreted factors.⁴⁶ Recent studies reported that the inhibition of mTOR with rapamycin triggers a negative feedback loop that results in the activation of Akt signaling.⁴⁷⁻⁴⁹ Sandri et al. demonstrated that phosphoinositide 3 (PI-3) kinase-Akt signaling inhibits Forkhead box O (Foxo) and atrogin-1 expression, which causes atrophy of myotubes and muscle fibers.⁵⁰ Akt signaling in skeletal muscle increases the production of MyHC isoforms and improves muscle mass and function.⁵¹

Apoptosis and senescence are well-documented cellular responses to DNA damage.^{52,53} MDSPCs isolated from progeroid *Ercc1*^{-Δ} mice display significantly greater amounts of apoptosis and cellular senescence compared to MDSPCs isolated from WT mice. This finding is consistent with previous studies in which cells isolated from progeroid *Ercc1*^{-Δ} mice showed higher rates of apoptosis and cellular senescence.^{11,54} The apoptosis and senescence of MDSPCs isolated from progeroid mice are reduced when mTOR is inhibited with rapamycin. Hence, the decreased capac-

ity for myogenic differentiation of MDSPCs could be due in part to an increase in the levels of apoptosis and cellular senescence.⁵⁵ The proliferation ability of *Ercc1*^{-Δ} MDSPCs was significantly lower than that of WT-MDSPCs, a result similar to that of a previous study from our laboratory.²¹ However, rapamycin did not appear to influence the proliferation capacity of *Ercc1*^{-Δ} MDSPCs (Fig. 1E).

This study has several limitations that should be noted. First, we did not evaluate the effects of rapamycin treatment using an in vivo model. We would like to pursue this line of in vivo research in the future, but it is clear that the dosage and timing of rapamycin treatment will need to be optimized prior to determining the effect of rapamycin on the accelerated aging phenotype displayed by *Ercc1*^{-Δ} mice. Second, we did not evaluate the effects of rapamycin treatment on the osteogenic differentiation capacities of *Ercc1*^{-Δ} MDSPCs. In terms of age-related functional decline, it is well known that reduced bone mineral density is a common feature of the aging skeleton. In a previous study, we showed that MDSPCs from *Ercc1*^{-Δ} mice have limited osteogenic potential.²¹ The effect of rapamycin on the multi-lineage differentiation potential of MDSPCs beyond myogenesis requires further investigation. Finally, musculoskeletal tissues are highly adaptable and many signaling pathways, such as Akt signaling and Wnt signaling, among others, regulate muscle remodeling; therefore, the implication of these signaling pathways on the beneficial effect of rapamycin on progeria MDSPCs remains to be elucidated.

In conclusion, our results demonstrate that inhibiting mTOR with rapamycin improves the myogenic differentiation potentials of progeroid *Ercc1*^{-Δ} MDSPCs by decreasing the percentage of cells undergoing apoptosis, attenuating the rate of senescence, and promoting autophagy. The results from our current study provide novel insights into the spontaneous and premature onset of age-related changes associated with progeria, and the role of mTOR on the accelerated aging of adult stem cells.

AUTHORS' CONTRIBUTIONS

KT, YK, and JH designed the research; KT, YK, ML, XM, and TY conducted the research; KT, YK, ML, PDR, and LJN analyzed the data; KT, YK, ML, JHC, RK, MK, FHF, and JH interpreted the data and drafted the manuscript; JH had primary responsibility for the final content. All authors have read and approved the final submitted manuscript.

ACKNOWLEDGMENTS

This project was funded in part by two NIH grants: R21 AG033907 (JH) and PO1 AG043376 (PR, JH, LN) and the Henry J. Mankin Endowed Chair at the University of Pittsburgh. The authors are grateful for the technical and scientific advice provided by Jessica Tebbets and Haizi Cheng, and the editorial assistance of Lavanya Rajagopalan, Bria King, and Ryan Warth.

REFERENCES

- Kirkwood TB. 2005. Understanding the odd science of aging. *Cell* 120:437–447.
- Vijg J. 2008. The role of DNA damage and repair in aging: new approaches to an old problem. *Mech Ageing Dev* 129:498–502.
- Vermeij WP, Hoeijmakers JH, Pothof J. 2016. Genome integrity in aging: human syndromes, mouse models, and therapeutic options. *Annu Rev Pharmacol Toxicol* 56:427–445.
- Ahmad A, Robinson AR, Duensing A, et al. 2008. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. *Mol Cell Biol* 28:5082–5092.
- Niedernhofer LJ, Odijk H, Budzowska M, et al. 2004. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. *Mol Cell Biol* 24:5776–5787.
- Sijbers AM, de Laat WL, Ariza RR, et al. 1996. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. *Cell* 86:811–822.
- Niedernhofer LJ, Garinis GA, Raams A, et al. 2006. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. *Nature* 444:1038–1043.
- Weeda G, Donker I, de Wit J, et al. 1997. Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. *Curr Biol* 7:427–439.
- Dolle ME, Kuiper RV, Roodbergen M, et al. 2011. Broad segmental progeroid changes in short-lived *Ercc1*(-Δ/Δ) mice. *Pathobiol Aging Age Relat Dis* 1. doi: 10.3402/pba.v1i0.7219
- Gregg SQ, Robinson AR, Niedernhofer LJ. 2011. Physiological consequences of defects in ERCC1-XPF DNA repair endonuclease. *DNA Repair (Amst)* 10:781–791.
- Cho JS, Kook SH, Robinson AR, et al. 2013. Cell autonomous and nonautonomous mechanisms drive hematopoietic stem/progenitor cell loss in the absence of DNA repair. *Stem Cells* 31:511–525.
- Harkema L, Youssef SA, de Bruin A. 2016. Pathology of mouse models of accelerated aging. *Vet Pathol* 53:366–389.
- Gregg SQ, Gutierrez V, Robinson AR, et al. 2012. A mouse model of accelerated liver aging caused by a defect in DNA repair. *Hepatology* 55:609–621.
- Schumacher B, van der Pluijm I, Moorhouse MJ, et al. 2008. Delayed and accelerated aging share common longevity assurance mechanisms. *PLoS Genet* 4:e1000161.
- Qu-Petersen Z, Deasy B, Jankowski R, et al. 2002. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. *J Cell Biol* 157:851–864.
- Gharraibeh B, Lu A, Tebbets J, et al. 2008. Isolation of a slowly adhering cell fraction containing stem cells from murine skeletal muscle by the preplate technique. *Nat Protoc* 3:1501–1509.
- Lavasani M, Lu A, Thompson SD, et al. 2013. Isolation of muscle-derived stem/progenitor cells based on adhesion characteristics to collagen-coated surfaces. *Methods Mol Biol* 976:53–65.
- Peng H, Wright V, Usas A, et al. 2002. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. *J Clin Invest* 110:751–759.
- Payne TR, Oshima H, Okada M, et al. 2007. A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts. *J Am Coll Cardiol* 50:1677–1684.
- Oshima H, Payne TR, Urish KL, et al. 2005. Differential myocardial infarct repair with muscle stem cells compared to myoblasts. *Mol Ther* 12:1130–1141.

21. Lavasani M, Robinson AR, Lu A, et al. 2012. Muscle-derived stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria model. *Nat Commun* 3:608.
22. Kim D, Kyung J, Park D, et al. 2015. Health span-extending activity of human amniotic membrane- and adipose tissue-derived stem cells in F344 rats. *Stem Cells Transl Med* 4:1144–1154.
23. Blagosklonny MV. 2008. Aging: ROS or TOR. *Cell Cycle* 7:3344–3354.
24. Kaerberlein M, Powers RW, 3rd, Steffen KK, et al. 2005. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. *Science* 310:1193–1196.
25. Vellai T, Takacs-Vellai K, Zhang Y, et al. 2003. Genetics: influence of TOR kinase on lifespan in *C. elegans*. *Nature* 426:620.
26. Harrison DE, Strong R, Sharp ZD, et al. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 460:392–395.
27. Ma XM, Blenis J. 2009. Molecular mechanisms of mTOR-mediated translational control. *Nat Rev Mol Cell Biol* 10:307–318.
28. Hansen M, Chandra A, Mitic LL, et al. 2008. A role for autophagy in the extension of lifespan by dietary restriction in *C. elegans*. *PLoS Genet* 4:e24.
29. Cavallini G, Donati A, Taddei M, et al. 2007. Evidence for selective mitochondrial autophagy and failure in aging. *Autophagy* 3:26–27.
30. Ravikumar B, Vacher C, Berger Z, et al. 2004. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat Genet* 36:585–595.
31. Mizushima N, Yoshimori T. 2007. How to interpret LC3 immunoblotting. *Autophagy* 3:542–545.
32. Rossi DJ, Bryder D, Seita J, et al. 2007. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. *Nature* 447:725–729.
33. Roobrouck VD, Ulloa-Montoya F, Verfaillie CM. 2008. Self-renewal and differentiation capacity of young and aged stem cells. *Exp Cell Res* 314:1937–1944.
34. Martin DE, Hall MN. 2005. The expanding TOR signaling network. *Curr Opin Cell Biol* 17:158–166.
35. Wullschlegel S, Loewith R, Hall MN. 2006. TOR signaling in growth and metabolism. *Cell* 124:471–484.
36. Ramos FJ. 2012. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. *Sci Transl Med* 4.
37. Chen C, Liu Y, Zheng P. 2009. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. *Sci Signal* 2:ra75.
38. Chen C, Liu Y, Liu R, et al. 2008. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. *J Exp Med* 205:2397–2408.
39. Feldman ME, Apsel B, Uotila A, et al. 2009. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. *PLoS Biol* 7:e38.
40. Selman C, Tullet JM, Wieser D, et al. 2009. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. *Science* 326:140–144.
41. Miller RA, Harrison DE, Astle CM, et al. 2011. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. *J Gerontol A Biol Sci Med Sci* 66:191–201.
42. Hands SL, Proud CG, Wyttenbach A. 2009. mTOR's role in ageing: protein synthesis or autophagy? *Aging (Albany NY)* 1:586–597.
43. Morselli E, Galluzzi L, Kepp O, et al. 2009. Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. *Aging (Albany NY)* 1:961–970.
44. Salemi S, Yousefi S, Constantinescu MA, et al. 2012. Autophagy is required for self-renewal and differentiation of adult human stem cells. *Cell Res* 22:432–435.
45. Blagosklonny MV. 2011. Progeria, rapamycin and normal aging: recent breakthrough. *Aging (Albany NY)* 3:685–691.
46. Takano-Ohmuro H, Mukaida M, Kominami E, et al. 2000. Autophagy in embryonic erythroid cells: its role in maturation. *Eur J Cell Biol* 79:759–764.
47. Sun SY, Rosenberg LM, Wang X, et al. 2005. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. *Cancer Res* 65:7052–7058.
48. Wan X, Harkavy B, Shen N, et al. 2007. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. *Oncogene* 26:1932–1940.
49. O'Reilly KE, Rojo F, She QB, et al. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res* 66:1500–1508.
50. Sandri M, Sandri C, Gilbert A, et al. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. *Cell* 117:399–412.
51. Blaauw B, Canato M, Agatea L, et al. 2009. Inducible activation of Akt increases skeletal muscle mass and force without satellite cell activation. *FASEB J* 23:3896–3905.
52. Vazquez A, Bond EE, Levine AJ, et al. 2008. The genetics of the p53 pathway, apoptosis and cancer therapy. *Nat Rev Drug Discov* 7:979–987.
53. Niedemhofer LJ, Robbins PD. 2008. Signaling mechanisms involved in the response to genotoxic stress and regulating lifespan. *Int J Biochem Cell Biol* 40:176–180.
54. Chen Q, Liu K, Robinson AR, et al. 2013. DNA damage drives accelerated bone aging via an NF- κ B-dependent mechanism. *J Bone Miner Res* 28:1214–1228.
55. Villeda SA, Luo J, Mosher KI, et al. 2011. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. *Nature* 477:90–94.